Cardiac events following radical radiotherapy for lung cancer
Dr Fei Sun - Leeds Cancer Centre, Leeds, UK
Cardiac events following radical radiotherapy for lung cancer ( Dr Fei Sun - Leeds Cancer Centre, Leeds, UK )
10 May 2019
ALK-positive NSCLC: Treatments and latest developments
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
ALK-positive NSCLC: Treatments and latest developments ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )
29 Apr 2019
ALK-positive NSCLC: Current landscape
Dr Antonio Passaro and Prof Rafal Dziadziuszko
ALK-positive NSCLC: Current landscape ( Dr Antonio Passaro and Prof Rafal Dziadziuszko )
29 Apr 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1  advanced NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )
18 Apr 2019
Entrectinib in NTRK fusion-positive non-small cell lung cancer
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Entrectinib in NTRK fusion-positive non-small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
18 Apr 2019
Using CT imaging to find radiomic signatures in surgically resected NSCLC
Giulia Mazzaschi - University Hospital Parma, Parma, Italy
Using CT imaging to find radiomic signatures in surgically resected NSCLC ( Giulia Mazzaschi - University Hospital Parma, Parma, Italy )
18 Apr 2019
The role of afatinib in patients with EGFR NSCLC
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
The role of afatinib in patients with EGFR  NSCLC ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )
18 Apr 2019
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination wit...
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )
15 Apr 2019
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplifie...
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )
15 Apr 2019
Using regionally delivered autologous mesothelin-targeted CAR T cells in the tre...
Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA
Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )
15 Apr 2019
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases
Dr Marina Garassino - National Tumor Institute, Milan, Italy
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
15 Apr 2019
MYSTIC: Developing biomarkers for metastatic NSCLC
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switze...
MYSTIC: Developing biomarkers for metastatic NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
11 Apr 2019